Category: News

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months ANN ARBOR, MI – December 22, 2020 ONL Therapeutics, Inc., a biopharmaceutical company…

ONL Therapeutics featured on the OIS Retina Podcast ANN ARBOR, MI – June 30, 2020 This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for…

ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204 ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study ANN ARBOR, MI – October 23, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient…

ONL Therapeutics Announces First-in-human Clinical Study With ONL1204 Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, MI – October 8, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the initiation of the company’s First-in-Human…

ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 Into First-in-Human Clinical Study Lead candidate ONL1204 will advance to Phase I clinical study in retinal detachment in late 2019 ANN ARBOR, MI – August 22, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with…

ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First In Human Clinical Trials David A. Esposito Appointed President and Chief Executive Officer as Company Accelerates Preparation of ONL1204 for Retinal Detachment Clinical Trial ANN ARBOR, MI – June 18, 2019 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision…

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials ANN ARBOR, MI – May 17, 2017 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a…

Novartis Steps in to Help Seed a Michigan Spinout’s Move into the Clinic with New Eye Drug Endpoints News Novartis has joined hands with some local investors in Michigan to come up with a small but significant $4.25 million A round… Read the Article

ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team Company Names New Board Member, Continues to Build Out Operations Team Through Appointment and Promotions  ANN ARBOR, MI – March 28, 2017  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases,…